Johnson & Johnson (NYSE:JNJ) will release its second quarter earnings report before the opening bell on Wednesday, July 15.

Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings of $2.85 per share, up from $2.77 per share in the year-ago period. The consensus estimate for Johnson & Johnson’s quarterly revenue is $25.05 billion. It reported $23.74 billion last year, according to Benzinga Pro.

On June 26, Johnson & Johnson announced additional data on IMAAVY throughout 12 abstracts at European Academy of Neurology 2026 Congress.

Johnson & Johnson shares rose 3.6% to close at $263.04 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

  • Guggenheim analyst Vamil Divan maintained a Buy rating and raised the price target from $266 to $270 on June 26, 2026. This analyst has an accuracy rate of 78%.
  • Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform with a price target of $265 on May 13, 2026. This analyst has an accuracy rate of 73%.
  • Barclays analyst Matt Miksic maintained the stock with an Equal-Weight rating and raised the price target from $234 to $255 on April 15, 2026. This analyst has an accuracy rate of 62%.
  • Stifel analyst Rick Wise maintained the stock with a Hold rating and raised the price target from $220 to $250 on April 15, 2026. This analyst has an accuracy rate of 68%.
  • Wells Fargo analyst Larry Biegelsen maintained the stock with an Overweight rating and raised the price target from $240 to $263 on April 15, 2026. This analyst has an accuracy rate of 63%.

Considering buying JNJ stock? Here’s what analysts think:

Photo via Shutterstock